Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7717-7730

  Billamboz, Muriel ^a   Bailly, Fabrice ^a   Barreca, Maria Letizia ^b   De Luca, Laura ^c   Mouscadet, Jean François ^d   Calmels, Christina ^e   Andréola, Marie Line ^e   Witvrouw, Myriam ^f   Christ, Frauke ^f   Debyser, Zeger ^f   Cotelle, Philippe ^a  

^a UNIV LILLE   (France)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d Ecole Normale Superieure de Cachan   (France)

^e University Victor Segalen   (France)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 FLUOROPHENYL) N (2 HYDROXY 1,3 DIOXO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YL)ACETAMIDE; 2 BENZYLOXY 7 (3,4 DIMETHOXYPHENYL)ISOQUINOLINE 1,3(2H,4H) DIONE; 2 HYDROXY 7 (4 HYDROXYPHENYL)ISOQUINOLINE 1,3(2H,4H) DIONE; 2 HYDROXY 7 IODOISOQUINOLINE 1,3(2H,4H) DIONE; 2 HYDROXY 7 NITROISOQUINOLINE 1,3(2H,4H) DIONE; 2 HYDROXY 7 PHENYLISOQUINOLINE 1,3(2H,4H) DIONE; 2 HYDROXY 7 [4 (TRIFLUOROMETHYL)PHENYL]ISOQUINOLINE 1,3(2H,4H) DIONE; 2 HYDROXYISOQUINOLINE 1,3(2H,4H) DIONE; 2 HYDROXYISOQUINOLINE 1,3(2H,4H) DIONE DERIVATIVE; 2,7 DIHYDROXYISOQUINOLINE 1,3(2H,4H) DIONE; 7 (3,4 DIHYDROXYPHENYL) 2 HYDROXYISOQUINOLINE 1,3(2H,4H) DIONE; 7 (4 FLUOROPHENYL) 2 HYDROXYISOQUINOLINE 1,3(2H,4H) DIONE; 7 AMINO 2 HYDROXYISOQUINOLINE 1,3(2H,4H) DIONE; 7 BROMO 2 HYDROXYISOQUINOLINE 1,3(2H,4H) DIONE; 7 CHLORO 2 HYDROXYISOQUINOLINE 1,3(2H,4H) DIONE; ELVITEGRAVIR; INTEGRASE INHIBITOR; N (2 HYDROXY 1,3 DIOXO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YL) 2 PHENYLACETAMIDE; N (2 HYDROXY 1,3 DIOXO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YL) 3 NITROBENZAMIDE; N (2 HYDROXY 1,3 DIOXO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YL) 4 FLUOROBENZAMIDE; N (2 HYDROXY 1,3 DIOXO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YL)ACETAMIDE; N (2 HYDROXY 1,3 DIOXO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YL)BENZAMIDE; N (2 HYDROXY 1,3 DIOXO 1,2,3,4 TETRAHYDROISOQUINOLIN 7 YL)PENTANAMIDE; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; RALTEGRAVIR; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONFORMATIONAL TRANSITION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; METAL BINDING; MOLECULAR INTERACTION; NONHUMAN; PROTEIN DOMAIN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STOICHIOMETRY;

EID: 58149083480     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8007085     Document Type: Article

References (54)

1. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-9154.
2. Maignan, S.; Guilloteau, J. P.; Zhou-Liu, Q.; Clément-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282, 359-368.
3. Makhija, M. T. Designing HIV integrase inhibitors: Shooting the last arrow. Curr. Med. Chem. 2006, 13, 2429-2441.
4. Lataillade, M.; Kozal, M. J. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 2006, 20, 489-501.
5. Dayam, R.; Deng, J.; Neamati, N. HIV-1 integrase inhibitors: 2003-2004 update. Med. Res. Rev. 2006, 26, 271-309.
6. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discovery 2005, 4, 236-248.
7. Johnson, A. A.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: A decade of research and two drugs in clinical trial. Curr. Top. Med. Chem. 2004, 4, 1059-1077.
8. Maurin, C.; Bailly, F.; Cotelle, P. Structure-activity relationships of HIV-1 integrase inhibitors: Enzyme-ligand interactions. Curr. Med. Chem. 2003, 10, 1795-1810.
9. Cotelle, P. Patented HIV-1 integrase inhibitors (1998-2005). Recent Patents Anti-Infect. Drug Discovery 2006, 1, 1-15.
10. Dejesus, E.; Berger, D.; Markowitz, M.; Cohen, C.; Hawkins, T.; Ruane, P.; Elion, R.; Farthing, C.; Zhong, C. L.; Cheng, A. K.; McColl, D.; Kearney, B. P. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquired Immune Defic. Syndr. 2006, 43, 1-5.
11. Grinsztejn, B.; Nguyen, B. Y.; Katlama, C.; Gatell, J. M.; Lazzarin, A.; Vittecoq, D.; Gonzalez, C. J.; Chen, J.; Harvey, C. M.; Isaacs, R. D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007, 369, 1261-1269.
12. Markowitz, M.; Morales-Ramires, J. O.; Nguyen, B. Y.; Kovacs, C. M.; Steigbigel, R. T.; Cooper, D. A.; Liporace, R.; Schwartz, R.; Isaacs, R.; Gilde, L. R.; Wenning, L.; Zhao, J.; Teppler, H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquired Immune Defic. Syndr. 2006, 43, 509-515.
13. Freed, E. O.; Martin, M. A. HIVs and their replication. In Fields Virology; Knipe, D., Howley, P., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2001; pp 1971-2042.
14. Telesnitsky, A.; Goff, S. P. Reverse transcriptase and the generation of viral DNA. In Retroviruses; Coffin, J. M., Hughes, S. H., Varmus, H. E., Eds.; Cold Spring Harbor Laboratory Press: Plainview, NY, 1997; pp 121-160.
15. Jacobo-Molina, A.; Ding, J.; Nanni, R. G.; Clark, A. D., Jr.; Lu, X.; Tantillo, C.; Williams, R. L.; Kamer, G.; Ferris, A. L.; Clark, P.; Hizi, A.; Hughes, S. H.; Arnold, E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6320-6324.
16. Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 1998, 282, 1669-1675.
17. (a) Yang, W.; Steitz, T. A. Recombining the structures of HIV integrase, RuvC and RNase H. Structure 1995, 3, 131-134.
18. (b) Haren, L.; Ton-Hoang, B.; Chandler, M. Integrating DNA: Transposases and retroviral integrases. Annu. Rev. Microbiol. 1999, 53, 245-281.
19. Andréola, M. L. Closely related antiretroviral agents as inhibitors of two HIV-1 enzymes, ribonuclease H and integrase: "Killing two birds with one stone". Curr. Pharm. Des. 2004, 10, 3713-3723.
20. Yang, W.; Hendrickson, W. A.; Crouch, R. J.; Satow, Y. Structure of ribonuclease H phased at 2 Å resolution by MAD analysis of the selenomethionyl protein. Science 1990, 249, 1398-1405.
21. Davies, J. F., II; Hostomska, Z.; Hostomsky, Z.; Jordan, S. R.; Matthews, D. A. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science 1991, 252, 88-95.
22. Kaushik, N.; Rege, N.; Yadav, P. N.; Sarafianos, S. G.; Modak, M. J.; Pandey, V. N. Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. Biochemistry 1996, 35, 11536-11546.
23. Patel, H. P.; Jacobo-Molina, A.; Ding, J.; Tantillo, C.; Clark, A. D.; Raag, R.; Nanni, R. G.; Hughes, S. H.; Arnold, E. Insights into DNA polymerisation mechanisms from structure and function analysis of HIV-1 reverse transcriptase. Biochemistry 1995, 34, 5351-5363.
24. Shaw-Reid, C. A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D. B.; Carroll, S. S.; Embrey, M.; Wai, J. S.; Miller, M. D.; Cole, J. L.; Hazuda, D. J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-y]-2,4-dioxobutanoic acid. J. Biol. Chem. 2003, 278, 2777-2780.
25. Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res. 2005, 65, 117-124.
26. de Soultrait, V.; Lozach, P.; Altmeyer, R.; Tarrago-Litvak, L.; Litvak, S.; Andréola, M. L. DNA aptamers derivated from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol. 2002, 324, 195-203.
27. Didierjean, J.; Isel, C.; Querré, F.; Mouscadet, J. F.; Aubertin, A. M.; Valnot, J. Y.; Piettre, S. R.; Marquet, R. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob. Agents Chemother. 2005, 49, 4884-4894.
28. Budihas, S.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona, M.; Parniak, M.; Crouch, R.; McMahon, J.; Beutler, J.; Le Grice, S. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res. 2005, 33, 1249-1256.
29. Semenova, E. A.; Johnson, A. A.; Marchand, C.; Davis, D. A.; Yarchoan, R.; Pommier, Y. Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by α-hydroxytropolones. Mol. Pharmacol. 2006, 69, 1454-1460.
30. Marchand, C.; Beutler, J. A.; Wamiru, A.; Budihas, S.; Möllmann, U.; Heinisch, L.; Mellors, J. W.; Le Grice, S. F.; Pommier, Y. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrob. Agents Chemother. 2008, 52, 361-364.
31. Hang, J. Q.; Rajendran, S.; Yang, Y.; Li, Y.; Wong Kai In, P.; Overton, H.; Parkes, K. E. B.; Cammack, N.; Martin, J. A.; Klumpp, K. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem. Biophys. Res. Commun. 2004, 317, 321-329.
32. Parkes, K. E. B.; Ermert, P.; Fassler, J.; Ives, J.; Martin, J. A.; Merrett, J. H.; Obrecht, D.; Williams, G.; Klumpp, K. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J. Med. Chem. 2003, 46, 1153-1164.
33. Klumpp, K.; Hang, J. Q.; Rajendran, S.; Yang, Y.; Derosier, A.; Wong Kai In, P.; Overton, H.; Parkes, K. E. B.; Cammack, N.; Martin, J. A. Two-metal-ion mechanism of RNA cleavage by HIV RNase H and mechanism based design of selective HIV RNase H inhibitors. Nucleic Acids Res. 2003, 31, 6852-6859.
34. Ames, D. E.; Grey, T. F. N-Hydroxyimides. II. J. Chem. Soc. 1955, 351, 3518-3521.
35. Horeau, A.; Jacques, J. Isocoumarins. Bull. Soc. Chim. Fr. 1948, 53-59.
36. Ungnade, H.; Nightingale, D.; French, H. The synthesis of 7-methoxyisoquinolone. J. Org. Chem. 1945, 10, 533-536.
37. Geffken, D. Zur cycliesierung von salicylsäureamiden und Salicylhydroxamsäuren von 1,1′-carbonyldiimidazol. Liebigs Ann. Chem. 1981, 1513-1514.
38. Sechi, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fisicaro, E.; Rogolino, D.; Gates, P.; Derudas, M.; Al-Mawsawi, L. Q.; Neamati, N. From ligand to complexes: Inhibition of human immunodeficiency virus type 1 integrase by β-diketo acid metal complexes. J. Med. Chem. 2006, 49, 4248-4260.
39. Barreca, M. L.; Ferro, S.; Rao, A.; De Luca, L.; Zappala, M.; Monforte, A. M.; Debyser, Z.; Witvrouw, M.; Chimirri, A. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 2005, 48, 7084-7088.
40. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
41. Grobler, J. A.; Stillmock, K.; Binghua, H.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J. Diketo acid inhibitor mechanism and integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6661-6666.
42. Rosemond, M. J.; St John-Williams, L.; Yamaguchi, T.; Fujishita, T.; Walsh, J. S. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: Role of human liver cytosolic aldo-keto reductases. Chem.-Biol. Interact. 2004, 147, 129-139.
43. Deng, J.; Dayam, R.; Al-Mawsawi, L. Q.; Neamati, N. Design of second generation HIV-1 integrase inhibitors. Curr. Pharm. Des. 2007, 13, 129-141.
44. Billich, A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Invest. Drugs 2003, 4, 206-209.
45. Cooper, D.; Gatell, J.; Rockstroh, J.; Katlama, C.; Yeni, P.; Lazzarin, A.; Chen, J.; Isaacs, R.; Teppler, H.; Nguyen, B. (for the BENCHMRK-Study Group)Results of BENCHMRK-1, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
46. Wang, Z.; Bennett, E. M.; Wilson, D. J.; Salomon, C.; Vince, R. Rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase. J. Med. Chem. 2007, 50, 3416-3419.
47. Sato, M.; Motomura, T.; Aramaki, H.; Matsuda, T.; Yamashita, M.; Ito, Y.; Kawakami, H.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Ikeda, S.; Kodama, E.; Matsuoka, M.; Shinkai, H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 2006, 49, 1506-1508.
48. De Luca, L.; Barreca, M. L.; Ferro, S.; Iraci, N.; Michiels, M.; Christ, F.; Debyser, Z.; Witvrouw, M.; Chimirri, A. A refined pharmacophore model for HIV-1 integrase inhibitors: Optimisation of potency in the 1H-benzylindole series. Bioorg. Med. Chem. Lett. 2008, 18, 2891-2895.
49. Debyser, Z.; Cherepanov, P.; Pluymers, W.; De Clercq, E. Assays for the evaluation of HIV-1 integrase inhibitors. Methods Mol. Biol. 2001, 160, 139-155.
50. Hwang, Y.; Rhodes, D.; Bushman, F. Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: Application to inhibitor isolation. Nucleic Acids Res. 2000, 28, 4884-4892.
51. Busschots, K.; Voet, A.; De Mayer, M.; Rain, J. C.; Emiliani, S.; Benarous, R.; Desender, L.; Debyser, Z.; Christ, F. Identification of the LEDGF/p75 binding site in HIV-1 integrase. J. Mol. Biol. 2007, 365, 1480-1492.
52. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
53. Moelling, K.; Schulze, T.; Diringer, H. Inhibition of human immunodeficiency virus type 1 RNase H by polysulfated polyanions. J. Virol. 1989, 63, 5489-5491.
54. Dufour, E.; Reinbolt, J.; Castroviejo, M.; Ehresmann, B.; Litvak, S.; Tarrago-Litvak, L.; Andreola, M. L. Cross-linking localization of a HIV-1 reverse transcriptase peptide involved in the binding of primer tRNALys3. J. Mol. Biol. 1999, 285, 1339-1346.